Literature DB >> 28920003

Cd226-/- natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo.

Ji Sung Kim1, Bo Ram Shin1, Hong Kyung Lee1, Jae Hee Lee1, Ki Hun Kim1, Jeong Eun Choi1, A Young Ji1, Jin Tae Hong1, Youngsoo Kim1, Sang-Bae Han1.   

Abstract

CD226 is an activating receptor expressed on natural killer (NK) cells, CD8+ T cells, and other immune cells. Upon binding to its ligands expressed on target cells, CD226 activates intracellular signaling that triggers cytokine production and degranulation in NK cells. However, the role of CD226 in contact dynamics between NK and cancer cells has remained unclear. Our time-lapse images showed that individual wild-type CD226+ NK cells contacted B16F10 melanoma cells for 23.7 min, but Cd226-/- NK cells only for 12.8 min, although both NK cell subsets showed equal contact frequency over 4 h. On the surface of B16F10 cells, CD226+ cells stayed at the same site with oscillating movement (named stable contact), while Cd226-/- NK cells moved around at a velocity of 4 μm/min (named unstable contact). Consequently, Cd226-/- NK cells did not kill B16F10 cells in vitro and did not inhibit their metastasis into the lung in vivo. Taken together, our data demonstrate that CD226 enables prolonged stable interaction between NK and cancer cells, which is needed for efficient killing of cancer cells.

Entities:  

Keywords:  Contact duration; NK cell-mediated cytotoxicity; contact dynamics; contact stability; melanoma

Year:  2017        PMID: 28920003      PMCID: PMC5593708          DOI: 10.1080/2162402X.2017.1338994

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  52 in total

1.  The mature activating natural killer cell immunologic synapse is formed in distinct stages.

Authors:  Jordan S Orange; K Eliza Harris; Milena M Andzelm; Markus M Valter; Raif S Geha; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-11       Impact factor: 11.205

2.  Granzyme B is recovered by natural killer cells via clathrin-dependent endocytosis.

Authors:  Pan Li; Guoying Zheng; Yan Yang; Chunguang Zhang; Ping Xiong; Yong Xu; Min Fang; Zheng Tan; Fang Zheng; Feili Gong
Journal:  Cell Mol Life Sci       Date:  2010-05-07       Impact factor: 9.261

3.  Coordinated expression of DNAM-1 and LFA-1 in educated NK cells.

Authors:  Monika Enqvist; Eivind Heggernes Ask; Elin Forslund; Mattias Carlsten; Greger Abrahamsen; Vivien Béziat; Sandra Andersson; Marie Schaffer; Anne Spurkland; Yenan Bryceson; Björn Önfelt; Karl-Johan Malmberg
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

Review 4.  Natural killer cell activation in mice and men: different triggers for similar weapons?

Authors:  Francesco Colucci; James P Di Santo; Paul J Leibson
Journal:  Nat Immunol       Date:  2002-09       Impact factor: 25.606

Review 5.  Improving natural killer cell cancer immunotherapy.

Authors:  Melissa M Berrien-Elliott; Rizwan Romee; Todd A Fehniger
Journal:  Curr Opin Organ Transplant       Date:  2015-12       Impact factor: 2.640

6.  Expression of DNAM-1 (CD226) on inflammatory monocytes.

Authors:  Anh Van Vo; Eri Takenaka; Akira Shibuya; Kazuko Shibuya
Journal:  Mol Immunol       Date:  2015-12-08       Impact factor: 4.407

7.  Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy.

Authors:  Alice C N Brown; Stephane Oddos; Ian M Dobbie; Juha-Matti Alakoskela; Richard M Parton; Philipp Eissmann; Mark A A Neil; Christopher Dunsby; Paul M W French; Ilan Davis; Daniel M Davis
Journal:  PLoS Biol       Date:  2011-09-13       Impact factor: 8.029

8.  Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.

Authors:  Cinzia Fionda; Maria Pia Abruzzese; Alessandra Zingoni; Alessandra Soriani; Biancamaria Ricci; Rosa Molfetta; Rossella Paolini; Angela Santoni; Marco Cippitelli
Journal:  BMC Cancer       Date:  2015-01-22       Impact factor: 4.430

9.  Accelerated tumor growth in mice deficient in DNAM-1 receptor.

Authors:  Akiko Iguchi-Manaka; Hirayasu Kai; Yumi Yamashita; Kai Shibata; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Teruhito Yasui; Hitoshi Kikutani; Kazuko Shibuya; Akira Shibuya
Journal:  J Exp Med       Date:  2008-11-24       Impact factor: 14.307

10.  Microchip Screening Platform for Single Cell Assessment of NK Cell Cytotoxicity.

Authors:  Karolin Guldevall; Ludwig Brandt; Elin Forslund; Karl Olofsson; Thomas W Frisk; Per E Olofsson; Karin Gustafsson; Otto Manneberg; Bruno Vanherberghen; Hjalmar Brismar; Klas Kärre; Michael Uhlin; Björn Önfelt
Journal:  Front Immunol       Date:  2016-04-05       Impact factor: 7.561

View more
  8 in total

Review 1.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

2.  CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell-mediated cytotoxicity.

Authors:  Eun Jae Park; Hye Won Jun; Ik Ho Na; Hong Kyung Lee; Jieun Yun; Hyung Sook Kim; Youngsoo Kim; Jin Tae Hong; Sang-Bae Han
Journal:  Arch Pharm Res       Date:  2021-12-14       Impact factor: 4.946

Review 3.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

4.  Functional visualization of NK cell-mediated killing of metastatic single tumor cells.

Authors:  Hiroshi Ichise; Shoko Tsukamoto; Tsuyoshi Hirashima; Yoshinobu Konishi; Choji Oki; Shinya Tsukiji; Satoshi Iwano; Atsushi Miyawaki; Kenta Sumiyama; Kenta Terai; Michiyuki Matsuda
Journal:  Elife       Date:  2022-02-03       Impact factor: 8.140

Review 5.  TIGIT in cancer immunotherapy.

Authors:  Joe-Marc Chauvin; Hassane M Zarour
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

6.  CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1.

Authors:  Xiangnan Du; Patricia de Almeida; Nick Manieri; Denise de Almeida Nagata; Thomas D Wu; Kristin Harden Bowles; Vidhyalakshmi Arumugam; Jill Schartner; Rafael Cubas; Stephanie Mittman; Vincent Javinal; Keith R Anderson; Søren Warming; Jane L Grogan; Eugene Y Chiang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-30       Impact factor: 11.205

7.  Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Authors:  Kristin C Hicks; Massimo Fantini; Renee N Donahue; Angie Schwab; Karin M Knudson; Sarah R Tritsch; Caroline Jochems; Paul E Clavijo; Clint T Allen; James W Hodge; Kwong Y Tsang; Jeffrey Schlom; Sofia R Gameiro
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

8.  Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Fas lpr mice.

Authors:  Hong Kyung Lee; Hyung Sook Kim; Minji Pyo; Eun Jae Park; Sundong Jang; Hye Won Jun; Tae Yong Lee; Kyung Suk Kim; Sang-Cheol Bae; Youngsoo Kim; Jin Tae Hong; Jaesuk Yun; Sang-Bae Han
Journal:  Theranostics       Date:  2020-08-13       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.